Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia

NCT07095127 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Immune Thrombocytopenia (ITP)

Interventions

DRUG: NVG-2089

Sponsor

Nuvig Therapeutics, Inc.